Screener
RxSight, Inc. RXST Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $13.35M-66.9% | $17.57M-37.2% | $19.95M+19.4% | $29.63M+77.2% | $40.36M+65.1% | ||
| $195.45M+4.4% | $200.31M-0.5% | $208.18M-5.6% | $197.88M-10.2% | $187.14M-10.4% | ||
| $18.52M-34.0% | $22.44M-27.5% | $23.38M-22.2% | $24.15M-4.8% | $28.06M+9.1% | ||
| $37.12M+48.1% | $34.87M+47.9% | $31.56M+43.4% | $28.95M+33.6% | $25.06M+28.9% | ||
| $327.4M+15.3% | $279.23M-3.2% | $287.46M-2.2% | $283.88M-1.0% | $283.87M+0.9% | ||
| $14.04M+5.9% | $13.23M+5.4% | $13.06M+5.2% | $13.1M+7.0% | $13.26M+6.5% | ||
| $352.7M+14.1% | $303.99M-2.9% | $311.81M-2.1% | $308.53M-0.6% | $309.01M+1.1% | ||
| $6.35M+89.5% | $7.12M+0.2% | $5.3M+16.5% | $3.38M-26.3% | $3.35M-34.3% | ||
| $6.88M— | —— | $3.26M— | —— | —— | ||
| $80.44M+295% | $27.38M+20.4% | $26.25M+1.5% | $22.29M-1.5% | $20.38M+3.9% | ||
| $89.36M+188% | $36.7M+8.8% | $36.13M-3.2% | $32.56M-1.9% | $31M+2.3% | ||
| $41K0.0% | $41K0.0% | $41K+2.5% | $41K+2.5% | $41K+2.5% | ||
| -$689.02M-7.3% | -$676.92M-7.4% | -$661.04M-6.3% | -$651.89M-5.8% | -$642.07M-5.3% | ||
| $263.34M-5.3% | $267.3M-4.3% | $275.68M-2.0% | $275.97M-0.5% | $278.01M+1.0% | ||
| $352.7M+14.1% | $303.99M-2.9% | $311.81M-2.1% | $308.53M-0.6% | $309.01M+1.1% |
FAQ
- What are RxSight, Inc.'s total assets?
- RxSight, Inc. (RXST) holds $352.7M in total assets, up 14.1% year over year.
- How much debt does RxSight, Inc. have?
- RxSight, Inc. carries $10.6M in total debt against $263.3M of shareholders' equity, a debt-to-equity ratio of 0.04.
- How much cash does RxSight, Inc. have?
- RxSight, Inc. holds $13.4M in cash and equivalents.
- Can RxSight, Inc. cover its short-term obligations?
- Its current ratio is 4.07 — current assets exceed current liabilities.
- Where does RxSight, Inc.'s balance sheet data come from?
- Every line is extracted from RxSight, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
